11-Apr-2020 | Market Research Store
An official at US subsidiary of Hitachi Chemical said that cell and gene therapy institutions are hesitating to embrace artificial intelligence. He further suggested that the manufacturers should think of automating their production. The Japanese conglomerate has opened a facility in Allendale, NJ. The facility is operated by Hitachi Chemical Advanced Therapeutics Solutions. According to Thomas Heathman, business leader of HCATS, has confirmed that the facility is specially designed and it will meet all the exclusive requirements of commercial cell and gene therapy products.
He said that it is always difficult to estimate the approval timelines and commercial demand for cell therapy. The infrastructure is built in such a way that the commercial customer needs will be met once the forecasts and needs are clear.
The design of the plant also includes data exchange. Systems such as LIMS and Manufacturing Execution System are being deployed to store data in electronic format. This will enable seamless data availability all through the facility.
He commented that other cell and gene therapy firms should focus on the data and interconnectivity. These firms are not quite ready to adopt advancements in the manufacturing systems such as artificial intelligence. It is high time that we turn our processes from manual to semi-automated. After this phase we should move forward to complete automation and then to AI. The advanced technologies will help in making vital process decisions on the basis of the manufacturing data.
It is estimated that the future advancements in the field of gene therapy will increase its growth rate in the coming years. The report published by the Market Research Store forecasts that the market anticipates to witness significant growth during the forecast period.